Andexanet alfa
- Generic Name
- Andexanet alfa
- Brand Names
- Andexxa, Ondexxya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1262449-58-0
- Unique Ingredient Identifier
- BI009E452R
- Background
Andexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals and was approved in in May 2018. It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban in cases of life-threatening...
- Indication
Andexanet alfa is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding . Andexxa has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban and rivaroxaban .
- Associated Conditions
- Severe Life-threatening, uncontrollable Bleeding
- Associated Therapies
- -
A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT05926349
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05898412
- Locations
- 🇳🇱
Research Site, Amsterdam, Netherlands
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5480
- Registration Number
- NCT05548777
- Locations
- 🇺🇸
Research Site, Agoura Hills, California, United States
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
- Conditions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04233073
- Locations
- 🇯🇵
Clinical Trial Site, Tokyo, Japan
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT03661528
- Locations
- 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.